CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients

被引:0
|
作者
Stephens, Dustin B. [1 ]
de Leon, Jose [2 ]
机构
[1] Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40536 USA
[2] Univ Kentucky, Coll Med, Dept Psychiat, Lexington, KY 40506 USA
关键词
CYP2D6; cytochrome P450; phenotype; self-harm; suicide; ultra-rapid; metabolizer; AMPLICHIP CYP450 TEST; CYP2C19; GENOTYPES; SEROTONIN; IMPACT; PHARMACOGENETICS; DEBRISOQUINE; BRAIN; PERSONALITY; ANTIDEPRESSANTS; POLYMORPHISM;
D O I
10.2217/pgs-2016-0086
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: Suicide accounts for over 800,000 deaths per year worldwide and is the tenth leading cause of mortality in USA. Several studies have investigated cytochrome P450 CYP2D6 ultra-rapid metabolizer (UM) phenotype in relation to suicidality, with mixed results. This study tested the hypothesis of increased suicide risk among CYP2D6 UMs. Patients & methods: Among the 4264 state psychiatric hospital inpatients included, 2435 (57%) reported a prior suicide attempt. Results: No association between UM status and attempted suicide was observed in bivariate (odds ratio: 0.87; 95% Cl: 0.531.25), multivariate (adjusted odds ratio: 0.89; 95% Cl: 0.55-1.46), or risk-stratified analyses. Conclusion: These results contrast with prior reports of increased suicidality among CYP2D6 UMs and highlight the pressing need to identify reliable screening methods to better address this persistent public health problem.
引用
收藏
页码:1295 / 1304
页数:10
相关论文
共 50 条
  • [41] Genetic polymorphism of CYP2D6 and CYP2C19 in a large French psychiatric population and clinical implication in extreme metabolizer patients
    Dupouey, J.
    Quaranta, S.
    Faget-Agius, C.
    Richieri, R.
    Laaroussi, A.
    Saut, N.
    Berge-Lefranc, J. L.
    Guilhaumou, R.
    Micallef, J.
    Lancon, C.
    Blin, O.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 61 - 61
  • [42] The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer
    AbdelRahman, SZ
    Anwar, WA
    AbdelAal, WE
    Ghoneim, MA
    Au, WW
    CANCER LETTERS, 1997, 119 (01) : 115 - 122
  • [43] Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype
    Corruble, E.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 (05): : 727 - 728
  • [44] Ultra-rapid CYP2D6-metabolic phenotype in a deprescription plan with prescription opioid dependence patients
    Almenara de Riquer, Susana
    Muriel Serrano, Javier
    del Barco, Guillermo
    Margarit Ferri, Cesar
    Barrachina Bernabeu, Jordi
    Planelles, Beatriz
    Inda Perez, Maria del Mar
    Morales Gonzalez, Domingo
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 32 - 32
  • [45] A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype
    Yokoi, T
    Kosaka, Y
    Chida, M
    Chiba, K
    Nakamura, H
    Ishizaki, T
    Kinoshita, M
    Sato, K
    Gonzalez, FJ
    Kamataki, T
    PHARMACOGENETICS, 1996, 6 (05): : 395 - 401
  • [46] Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
    Martinez de Duenas, Eduardo
    Ochoa Aranda, Enrique
    Blancas Lopez-Barajas, Isabel
    Ferrer Magdalena, Teresa
    Bandres Moya, Fernando
    Chicharro Garcia, Luis Miguel
    Gomez Capilla, Jose A.
    Zafra Ceres, Mercedes
    de Haro, Tomas
    Romero Llorens, Regina
    Ferrer Albiach, Carlos
    Ferriols Lisart, Rafael
    Chover Lara, Dolores
    Lopez Rodriguez, Angela
    Munarriz Ferrandis, Javier
    Olmos Anton, Santiago
    BREAST, 2014, 23 (04): : 400 - 406
  • [47] Supervised Classification of CYP2D6 Genotype and Metabolizer Phenotype With Postmortem Tramadol-Exposed Finns
    Wendt, Frank R.
    Novroski, Nicole M. M.
    Rahikainen, Anna-Liina
    Sajantila, Antti
    Budowle, Bruce
    AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY, 2019, 40 (01): : 8 - 18
  • [48] Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate
    Seeringer, Angela
    Brockmoeller, Juergen
    Bauer, Steffen
    Kirchheiner, Julia
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 883 - 888
  • [49] Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate
    Angela Seeringer
    Jürgen Brockmöller
    Steffen Bauer
    Julia Kirchheiner
    European Journal of Clinical Pharmacology, 2008, 64
  • [50] Prospective CYP2D6 genotyping in psychiatric inpatients. A preliminary report.
    Steimer, W
    Bachofer, J
    Popp, J
    Messner, B
    Heres, S
    Kissling, W
    Leucht, S
    CLINICAL CHEMISTRY, 2004, 50 (06) : A136 - A136